BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
Jul 02, 2007
 |  BC Extra  |  Clinical News

Newron reports ralfinamide results

Newron (SWX:NWRN) said that in the Phase II 001 trial in 272 neuropathic pain patients, ralfinamide met the primary endpoint of safety and tolerability, but failed to significantly reduce pain...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >